Cannabis Pain Research May Be Measuring the Wrong Things, Experts Argue | Research

The takeaway

A perspective piece argues clinical trials miss cannabis's true pain benefits by focusing on pain severity rather than outcomes patients value, like psychological coping, sleep, and opioid substitution.

Pain researchers, clinical trial designers, medical cannabis policymakers

Cannabis pain trials may miss real benefits by focusing on pain severity alone

What the researchers found

While clinical trials show inconsistent evidence for cannabis reducing pain severity, qualitative research reveals patients value cannabis because it changes their psychological response to pain and improves sleep, social functioning, and ability to reduce opioid use. The authors argue these outcomes should be primary endpoints in future trials.

Why it matters

If clinical trials keep measuring the wrong outcomes, they will continue to produce ambiguous results that do not reflect real-world patient benefits, leading to policy confusion.

The numbers in context

Perspective references existing RCTs and qualitative studies without novel data. Identifies sleep quality, role/social functioning, opioid substitution, and psychological coping as understudied outcomes.

How the study worked

Expert perspective piece reviewing the disconnect between RCT findings on cannabis for chronic pain and patient-reported experiences from qualitative research.

What this study cannot tell us

Perspective piece without new empirical data. The proposed outcomes are harder to standardize and measure than pain severity. Patient perceptions may not always align with objective health outcomes.

How to read the evidence

Expert perspective piece from established researchers, but presents argument rather than new evidence.

When this study was published

2025 perspective piece calling for paradigm shift in cannabis-pain research.

The bigger picture

The gap between what trials measure and what patients experience is a fundamental problem in cannabis-pain research. Patient-centered outcome measures could transform the evidence base and clarify cannabis's actual therapeutic role.

Questions still open

Would patient-centered outcomes change the evidence picture for cannabis and pain? How should opioid substitution be measured in trials? Can qualitative findings be translated into validated outcome measures?

Common questions

Does cannabis actually help with chronic pain?

Clinical trials show mixed results for pain reduction, but patients consistently report benefits. This perspective argues the trials are measuring the wrong things. Many patients value cannabis for its effects on coping, sleep, and opioid reduction rather than direct pain relief.

What should cannabis pain research measure?

The authors call for trials to focus on outcomes patients care about: psychological response to pain, sleep quality, social functioning, and ability to reduce opioid medications. Traditional pain severity may not capture cannabis's true therapeutic value.

Read the original research

Looking beyond traditional pain outcomes to better evaluate cannabis's true potential and limitations in chronic pain management.

Experimental and clinical psychopharmacology, 33(5), 425-429

View on PubMed ↗Publisher’s paper ↗

Citation

Mun, Chung Jung; Thrul, Johannes; Epstein, David H. (2025). Looking beyond traditional pain outcomes to better evaluate cannabis's true potential and limitations in chronic pain management.. Experimental and clinical psychopharmacology, 33(5), 425-429. https://doi.org/10.1037/pha0000795